Follow

Submissions from 2019

Link

Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis (Nature Immunology, (2019), 20, 7, (902-914), 10.1038/s41590-019-0398-x), A. Arazi, D. A. Rao, C. C. Berthier, A. Davidson, Z. Liu, J. Hoover, R. A. Furie, B. Diamond, A. Davidson, C. Fonseka, and +60 additional authors

Link

The immune cell landscape in kidneys of patients with lupus nephritis, A. Arazi, D. A. Rao, C. C. Berthier, A. Davidson, Z. Liu, P. J. Hoover, R. A. Furie, B. Diamond, A. Davidson, C. Fonseka, and +60 additional authors

PDF

An interim report of the scleroderma clinical trials consortium working groups, M. Baron, B. Kahaleh, E. J. Bernstein, L. Chung, P. J. Clements, C. Denton, R. T. Domsic, N. Ferdowsi, S. Narain, A. Vacca, and +12 additional authors

Link

A case of dolutegravir-induced cutaneous small vessel vasculitis, B. S. Bennett, N. Mikaberidze, and L. M. Ahmadi

Link

Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology, E. A. Butler, M. Baron, A. B. Fogo, T. Frech, C. Ghossein, E. Hachulla, S. Hoa, S. R. Johnson, S. Narain, U. A. Walker, and +64 additional authors

PDF

Delivering Challenging News: An Illness-Trajectory Communication Curriculum for Multispecialty Oncology Residents and Fellows, D. Cannone, M. Atlas, A. Fornari, M. L. Barilla-LaBarca, and M. Hoffman

Link

Novel paradigms in systemic lupus erythematosus, T. Doerner and R. Furie

PDF

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus, R. Furie, V. P. Werth, J. F. Merola, L. Stevenson, T. L. Reynolds, H. Naik, W. Wang, R. Christmann, A. Gardet, N. Franchimont, and +6 additional authors

Link

Maintenance of certification status and performance on a set of process measures., M. Jarrett

PDF

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol, Y. K. Onno Teng, I. N. Bruce, B. Diamond, R. A. Furie, R. F. Van Vollenhoven, D. Gordon, J. Groark, R. B. Henderson, M. Oldham, and P. P. Tak

Link

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus., R. Ramsey-Goldman, R. V. Alexander, E. M. Massarotti, D. J. Wallace, S. Narain, C. Arriens, C. E. Collins, A. Saxena, C. Putterman, A. Weinstein, and +3 additional authors

PDF

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE., D. J. Wallace, R. V. Alexander, T. O'Malley, A. Khosroshahi, M. Hojjati, K. Loupasakis, J. Alper, Y. Sherrer, S. Narain, T. Dervieux, and +6 additional authors

Link

Baricitinib for systemic lupus erythematosus – Authors' reply, D. J. Wallace, R. A. Furie, Y. Tanaka, S. de Bono, and R. W. Hoffman

PDF

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus, D. J. Wallace, E. M. Ginzler, J. T. Merrill, R. A. Furie, W. Stohl, W. W. Chatham, A. Weinstein, J. D. McKay, W. J. McCune, A. Heath, and +4 additional authors

Submissions from 2018

Link

Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis, R. Aggarwal, G. Marder, D. C. Koontz, P. Nandkumar, Z. Qi, and C. V. Oddis

PDF

Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature, E. Anderson, B. Shah, A. Davidson, and R. Furie

Link

TUBERCULOUS CHOROIDITIS IN PATIENT WITH VOGT-KOYANAGI-HARADA DISEASE., E. W. Anderson, L. El Khoury, J. S. Schwartzman-Morris, J. Jonisch, and N. R. Goldberg

PDF

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting., J. C. Berkowitz, J. Stein-Fishbein, S. Khan, R. Furie, and K. S. Sultan

PDF

Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis, J. C. Cooper, K. Rouster-Stevens, T. B. Wright, J. J. Hsu, M. S. Klein-Gitelman, S. P. Ardoin, L. E. Schanberg, H. I. Brunner, B. A. Eberhard, E. von Scheven, and +6 additional authors

PDF

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States, R. A. Furie, D. J. Wallace, C. Aranow, J. Fettiplace, B. Wilson, P. Mistry, D. A. Roth, and D. Gordon

Link

Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE, R. Furie, L. Wang, G. Illei, and J. Drappa

PDF

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids, Y. Hu, J. A. Carman, D. Holloway, S. Kansal, L. Fan, C. Goldstine, D. Lee, J. E. Somerville, R. Furie, S. G. Nadler, and +7 additional authors

Evacuate or shelter in place: A view from the water’s edge, M. P. Jarrett, Z. Schwartz, M. Solazzo, and E. Tangney

Link

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index, K. C. Kalunian, M. B. Urowitz, D. Isenberg, J. T. Merrill, M. Petri, R. A. Furie, M. Morgan-Cox, R. Taha, S. Watts, M. D. Linnik, and +1 additional author

PDF

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis, D. J. Lovell, J. A. Dare, M. Francis-Sedlak, J. Ball, B. D. LaMoreaux, E. Von Scheven, A. Reinhardt, R. Jerath, B. Gottlieb, R. J. Holt, and +6 additional authors

PDF

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE., J. T. Merrill, M. A. Petri, J. Buyon, R. Ramsey-Goldman, K. Kalunian, C. Putterman, J. Conklin, R. A. Furie, and T. Dervieux

Link

Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus, J. K. Presto, L. G. Okon, R. Feng, D. J. Wallace, R. Furie, D. Fiorentino, and V. P. Werth

Link

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial, D. J. Wallace, R. A. Furie, Y. Tanaka, K. C. Kalunian, M. Mosca, M. A. Petri, T. Dörner, M. H. Cardiel, I. N. Bruce, R. W. Hoffman, and +7 additional authors

Submissions from 2016

PDF

Development of a novel renal activity index of lupus nephritis in children & young adults, H. I. Brunner, M. Bennett, K. Abulaban, M. Klein-Gitelman, K. O'Neil, L. Tucker, S. Ardoin, K. Rouster-Stevens, B. A. Eberhard, P. Devarajan, and +8 additional authors

Link

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, J. T. Merrill, R. F. van Vollenhoven, J. P. Buyon, R. A. Furie, W. Stohl, M. Morgan-Cox, C. Dickson, P. W. Anderson, C. Lee, T. Dorner, and +1 additional author

PDF

Validation of the lupus nephritis clinical indices in childhood-onset systemic lupus erythematosus, R. Mina, K. Abulaban, M. Klein-Gitelman, A. Eberhard, S. Ardoin, N. Singer, K. Onel, L. Tucker, K. O'Neil, H. I. Brunner, and +8 additional authors

PDF

Increased pretreatment serum IFN-beta/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis, T. Wampler Muskardin, P. Vashisht, J. M. Dorschner, M. A. Jensen, B. S. Chrabot, M. Kern, J. R. Curtis, R. Furie, P. K. Gregersen, T. B. Niewold, and +14 additional authors

Submissions from 2015

Link

Methods for reducing sepsis mortality in emergency departments and inpatient units, M. E. Doerfler, J. D'Angelo, D. Jacobsen, M. P. Jarrett, A. I. Kabcenell, K. D. Masick, D. Parmentier, K. L. Nelson, and L. Stier

Link

Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis, R. Furie, K. Toder, and E. Zapantis

PDF

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices, J. S. Hui-Yuen, A. Reddy, J. Taylor, X. Li, A. H. Eichenfield, L. M. Bermudez, A. J. Starr, L. F. Imundo, R. A. Furie, A. Askanase, and +7 additional authors

PDF

Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus, R. Mina, M. S. Klein-Gitelman, S. Nelson, B. A. Eberhard, G. Higgins, N. G. Singer, K. Onel, L. Tucker, K. M. O'Neil, H. I. Brunner, and +4 additional authors

Link

Efficacy of an Interinstitutional Mentoring Program Within Pediatric Rheumatology., L. N. Moorthy, E. Muscal, M. Riebschleger, M. Klein-Gitelman, L. E. Nigrovic, J. R. Horon, K. Rouster-Stevens, P. J. Ferguson, B. A. Eberhard, P. A. Nigrovic, and +3 additional authors

Link

Treatment Algorithms in Systemic Lupus Erythematosus, C. Muangchan, R. F. van Vollenhoven, S. R. Bernatsky, C. D. Smith, M. Hudson, M. Inanc, N. F. Rothfield, P. T. Nash, R. A. Furie, J. E. Pope, and +4 additional authors

Link

Reply to: Hydroxychloroquine treatment in SLE, J. E. Pope, N. F. Rothfield, R. Ramsey-Goldman, C. D. Smith, S. R. Bernatsky, R. A. Furie, M. Hudson, R. Burgos-Vargas, J. L. Senecal, C. Muangchan, and +4 additional authors

Link

Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project, S. Ringold, A. Hendrickson, L. Abramson, T. Beukelman, P. R. Blier, J. Bohnsack, E. C. Chalom, H. L. Gewanter, B. Gottlieb, R. E. Sobel, and +26 additional authors

Link

Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study, D. J. Wallace, K. Hobbs, M. E. Clowse, M. Petri, V. Strand, M. Pike, J. T. Merrill, P. Leszczynski, R. Furie, C. Gordon, and +9 additional authors

Submissions from 2014

Link

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study, R. A. Furie, G. Leon, M. Thomas, M. A. Petri, A. D. Chu, C. Hislop, R. S. Martin, and M. A. Scheinberg

PDF

Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study, R. Furie, K. Nicholls, T. T. Cheng, F. Houssiau, R. Burgos-Vargas, S. L. Chen, J. L. Hillson, S. Meadows-Shropshire, M. Kinaszczuk, and J. T. Merrill

PDF

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials, R. Furie, M. A. Petri, V. Strand, D. D. Gladman, Z. J. Zhong, and W. W. Freimuth

Link

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus, E. M. Ginzler, D. J. Wallace, J. T. Merrill, R. A. Furie, W. Stohl, W. W. Chatham, A. Weinstein, J. D. McKay, W. J. McCune, M. A. Petri, and +2 additional authors

PDF

A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort, R. L. Gross, J. S. Schwartzman-Morris, M. Krathen, G. Reed, H. Chang, K. C. Saunders, M. C. Fisher, J. D. Greenberg, C. Putterman, A. Broder, and +3 additional authors

PDF

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis, N. T. Ilowite, K. Prather, Y. Lokhnygina, L. E. Schanberg, M. Elder, D. Milojevic, J. W. Verbsky, S. J. Spalding, B. S. Gottlieb, C. I. Sandborg, and +12 additional authors

Link

AMIGO: A Novel Approach to the Mentorship Gap in Pediatric Rheumatology, P. A. Nigrovic, E. Muscal, M. Riebschleger, L. N. Moorthy, H. I. Brunner, B. A. Eberhard, M. Klein-Gitelman, S. Prahalad, and R. Schneider

PDF

Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS, V. Proulle, R. A. Furie, G. Merrill-Skoloff, B. C. Furie, and B. Furie

PDF

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements, C. Putterman, R. Furie, R. Ramsey-Goldman, A. Askanase, J. Buyon, K. Kalunian, W. W. Chatham, E. Massarotti, K. Kirou, T. Dervieux, and +10 additional authors

PDF

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry, R. E. Sobel, D. J. Lovell, H. I. Brunner, J. E. Weiss, P. W. Morris, B. S. Gottlieb, E. C. Chalom, L. K. Jung, K. B. Onel, E. H. Giannini, and +6 additional authors

Link

Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors, C. A. Wallace, E. H. Giannini, S. J. Spalding, P. J. Hashkes, K. M. O'Neil, A. S. Zeft, I. S. Szer, S. Ringold, B. S. Gottlieb, D. J. Lovell, and +12 additional authors

Link

Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis, C. A. Wallace, S. Ringold, J. Bohnsack, S. J. Spalding, H. I. Brunner, D. Milojevic, L. E. Schanberg, G. C. Higgins, B. S. Gottlieb, A. Hendrickson, and +4 additional authors